IL15 and neoplasm: Conversely, our team's anti-PD-L1/IL-15 immunocytokine (LH01), possessing a similar homodimeric structure with the anti-PD-1/IL-15, demonstrated no notable toxicities upon intraperitoneal administration three times at a dosage of 5 mg/kg (100 μg) in MC38 tumor-bearing mice.41